drugset / Trial / NCT04830358

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

NCT04830358

Phase 1 Completed 60 enrolled EuBiologics Co.,Ltd
RandomizedParallel-groupSingle-blindPrevention

Summary

The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.

Timeline

Start
2020-05-28
Primary completion
2020-08-14
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EuPCV15 Vaccine Intramuscular
Comparator Prevnar 13 Vaccine Intramuscular